National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

  • Daratumumab (Darzalex®) combination therapy - March 15, 2019

    The NCPE recommends that daratumumab combination (Darzalex®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Liraglutide (Victoza®) - March 7, 2019

    The NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Patiromer (Veltassa®) - February 13, 2019

    The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. 

  • Pertuzumab (Perjeta®) for Adjuvant HER2 positive breast cancer - January 31, 2019

    The NCPE recommends that pertuzumab (in combination with trastuzumab and chemotherapy) for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease), not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.

  • Alectinib (Alecensa®) - January 15, 2019

    Following assessment of the applicant’s submission the NCPE recommends that alectinib (Alecensa®), for the first line treatment of adult patients with ALK-positive advanced NSCLC, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

  • Lesinurad (Zurampic®) - December 6, 2018

    The NCPE recommends that lesinurad not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Dinutuximab beta (Qarziba®) - October 22, 2018

    Following assessment of the applicant’s submission, the NCPE recommends that dinutuximab beta (Qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.

  • Avelumab (Bavencio®) - October 9, 2018

    The NCPE recommends that avelumab (Bavencio®) for the treatment of metastatic Merkel Cell Carcinoma not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.

  • Ocrelizumab (Ocrevus®) for PPMS - October 9, 2018

    The NCPE recommends that ocrelizumab (Ocrevus®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Atezolizumab (Tecentriq®) - September 25, 2018

    The NCPE recommends that atezolizumab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.